Evaluation of the Healing of the Pilonidal Cyst After 1940 nm Laser Treatment (PILOLAS 1940)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Lyon, France, 69009
- Recruiting
- Clinique de la Sauvegarde
-
Contact:
- Benjamin DARNIS, Dr
- Phone Number: +33 04-37-49-66-77
- Email: benjamin.darnis@hotmail.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who did not object to the collection of their data
- Patients who underwent surgery for a pilonidal cyst using 1940 nm laser treatment
Exclusion Criteria:
Patients with a history of pilonidal cyst surgery
- Patients who underwent emergency surgery for an abscess
- Patients already included in another therapeutic study protocol
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
LASER 1940
Patient who underwent surgery for a pilonidal cyst using 1940 nm laser treatment
|
pilonidal cyst using 1940 nm laser treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HEALING
Time Frame: 1 Month
|
The main objective is to evaluate the healing rate of the pilonidal sinus one month after treatment with Er-YAG laser 1940 nm.
Wound healing at one month, defined by the absence of a dressing, is the main evaluation criterion.
|
1 Month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recidivism
Time Frame: 6 Month
|
Recidivism is defined by: - The presence of persistent troubling symptoms 6 months after the surgery: suppuration, recurrent wound dehiscence, lack of healing despite care deemed optimal by the expert, reactivation/recurrence of abscesses.
- The presence of a characteristic image on MRI if this examination has been carried out: subcutaneous collection, in hyper T2.
|
6 Month
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2024-06-045-P-ERAMD0619
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.